Back to search

Article

Evaluation of SLCA62 and CYP2D6 Polymorphisms’ Effects on Atomoxetine Treatment in Attention Deficit and Hyperactivity Disorder

2024-05-30

Abstract excerpt

<title>Abstract</title> <p>Background There is insufficient replicated data to establish a relationship between the polymorphisms of NET/SLC6A2 and the efficacy of Atomoxetine (ATX) treatment. We focused on evaluating the effect of top-line single nucleotide polymorphisms (SNPs) in SLC6A2 and CYP2D6 on the ATX treatment response in Attention-Deficit and Hyperactivity Disorder (ADHD). Methods Of 160 patient reco...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
4733b597-6999-5044-9546-174545c59f82
DOI
10.21203/rs.3.rs-4402227/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Evaluation of SLCA62 and CYP2D6 Polymorphisms’ Effects on Atomoxetine Treatment in Attention Deficit and Hyperactivity DisorderDOI 10.21203/rs.3.rs-4402227/v1
Evaluation of SLC6A2 and CYP2D6 polymorphisms' effects on atomoxetine treatment in attention deficit and hyperactivity disorder.Semantic proximity
Role of the norepinephrine transporter polymorphisms in atomoxetine treatment: From response to side effects in children with ADHD.Semantic proximity
Clinical Pharmacogenetics Implementation Consortium Guideline for <scp>Cytochrome P450 (<i>CYP</i>)</scp><i>2D6</i> Genotype and Atomoxetine TherapySemantic proximity
A haplotype of the norepinephrine transporter (Net) gene Slc6a2 is associated with clinical response to atomoxetine in attention-deficit hyperactivity disorder (ADHD).Semantic proximity
Atomoxetine pharmacogenetics: associations with pharmacokinetics, treatment response and tolerability.Semantic proximity
Dopamine Transporter and CYP2D6 Gene Relationships with Attention-Deficit/Hyperactivity Disorder Treatment Response in the Methylphenidate and Atomoxetine Crossover Study.Semantic proximity
Post-treatment symptomatic improvement of the eastern Indian ADHD probands is influenced by CYP2D6 genetic variations.Semantic proximity
Variants of Dopamine Beta Hydroxylase Gene Moderate Atomoxetine Response in Children with Attention-Deficit/Hyperactivity Disorder.Semantic proximity
Individualized atomoxetine response and tolerability in children with ADHD receiving different dosage regimens: the need for CYP2D6 genotyping and therapeutic drug monitoring to dance together.Semantic proximity
Adrenergic neurotransmitter system transporter and receptor genes associated with atomoxetine response in attention-deficit hyperactivity disorder children.Semantic proximity
Personalizing Atomoxetine Dosing in Children with ADHD: What Can We Learn from Current Supporting EvidenceSemantic proximity
CYP2D6 predicted metabolizer status and safety in adult patients with attention-deficit hyperactivity disorder participating in a large placebo-controlled atomoxetine maintenance of response clinical trial.Semantic proximity
Select a neighboring publication to make it the new centre.